A key element of the investment is the construction of a biologics flex factory in Upper Merion, Pennsylvania, where GSK already operates other facilities. Work on the site is scheduled to begin next year. The new factory will produce medicines for respiratory diseases and cancer, supported by artificial intelligence to optimize operations and manufacturing processes.
In addition to the new factory, GSK will introduce AI and digital technologies at its existing five US manufacturing sites, located in Maryland, Montana, North Carolina, and Pennsylvania. The plan also includes new spaces for drug substance manufacturing, expanded auto-injector capabilities, and additional assembly areas. These upgrades are expected to enhance efficiency and support the company’s long-term production strategy.
Emma Walmsley, Chief Executive of GSK, highlighted the significance of the investment: “Alongside the many longstanding and vital shared interests that connect the UK and the US, is advancing life sciences to get ahead of disease. This week’s state visit brings together two countries that have led the world in science and healthcare innovation.”
The $1.2 billion commitment underscores GSK’s intention to further develop its presence in the US pharmaceutical market. By expanding capabilities in biologics and integrating advanced technologies, the company aims to strengthen its position in producing medicines that address high-demand therapeutic areas.
This announcement comes amid wider industry trends, as other pharmaceutical companies, including Belgium-based UCB, have also outlined investment plans for US manufacturing facilities. Market analysts point to regulatory and trade developments as drivers behind the shift toward reinforcing local production capacity.
GSK’s investment reflects a dual strategy of enhancing scientific innovation and securing long-term supply chain resilience. By building new infrastructure and deploying digital tools, the company seeks to accelerate the development and delivery of critical medicines, contributing to improved healthcare outcomes.
The project also highlights the increasing role of AI in pharmaceutical production, particularly in streamlining processes, reducing costs, and maintaining product quality. With respiratory diseases and cancer remaining key global health challenges, the new Pennsylvania factory is expected to play an important role in meeting medical needs.
As GSK moves forward with these initiatives, the company emphasizes its commitment to scientific leadership, collaboration, and technological advancement. The US investment, combined with ongoing global projects, positions GSK to respond effectively to growing healthcare demands in the coming years.
